MDT

84.7

+3.42%↑

VEEV

218.11

+5.26%↑

A

105.07

+3.9%↑

HQY

83.49

+8.91%↑

PDCO

30.95

+0.52%↑

MDT

84.7

+3.42%↑

VEEV

218.11

+5.26%↑

A

105.07

+3.9%↑

HQY

83.49

+8.91%↑

PDCO

30.95

+0.52%↑

MDT

84.7

+3.42%↑

VEEV

218.11

+5.26%↑

A

105.07

+3.9%↑

HQY

83.49

+8.91%↑

PDCO

30.95

+0.52%↑

MDT

84.7

+3.42%↑

VEEV

218.11

+5.26%↑

A

105.07

+3.9%↑

HQY

83.49

+8.91%↑

PDCO

30.95

+0.52%↑

MDT

84.7

+3.42%↑

VEEV

218.11

+5.26%↑

A

105.07

+3.9%↑

HQY

83.49

+8.91%↑

PDCO

30.95

+0.52%↑

Search

Myriad Genetics Inc

Atvērts

SektorsVeselības aprūpe

8.11 1.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.87

Max

8.31

Galvenie mērījumi

By Trading Economics

Ienākumi

-20M

-43M

Pārdošana

-2.7M

211M

EPS

0.03

Peļņas marža

-20.18

Darbinieki

2,700

EBITDA

19M

-2.2M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+97.77% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-328M

811M

Iepriekšējā atvēršanas cena

6.86

Iepriekšējā slēgšanas cena

8.11

Ziņu noskaņojums

By Acuity

26%

74%

70 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. apr. 23:56 UTC

Top Ziņas

Australian Consumer Confidence Firms Despite Market Falls

2025. g. 7. apr. 23:45 UTC

Karstas akcijas

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

2025. g. 7. apr. 21:36 UTC

Galvenie tirgus virzītāji

Medicare Insurer Shares Rise on Plans for Higher Payment Rates

2025. g. 7. apr. 21:11 UTC

Galvenie tirgus virzītāji

Broadcom Authorizes $10 Billion Share Repurchase Program

2025. g. 7. apr. 23:48 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2025. g. 7. apr. 23:47 UTC

Tirgus saruna

Gold Edges Lower Amid More Cautious Near-Term Outlook -- Market Talk

2025. g. 7. apr. 23:34 UTC

Top Ziņas

Apple Users Rush to Upgrade iPhones Ahead of Potential Tariffs-Related Price Hikes -- WSJ

2025. g. 7. apr. 22:18 UTC

Top Ziņas

Health Insurer Stocks Jump After Medicare Boosts Payment Rates -- Barrons.com

2025. g. 7. apr. 21:43 UTC

Tirgus saruna

Oil Producers Choosing Returns Over Growth In Tariffs Fallout -- Market Talk

2025. g. 7. apr. 21:37 UTC

Tirgus saruna

Canada Faces Financial Crisis-Like Symptoms That Rate Cuts Won't Cure -- Market Talk

2025. g. 7. apr. 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Infineon: All-Cash Transaction to Be Financed From Existing Liquidity and Additional Debt >IFX.FF

2025. g. 7. apr. 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Infineon: Transaction Combines Infineon's Portfolio for Automotive Microcontrollers With Automotive Ethernet Business of Marvell, Accelerating Infineon's System Capabilities for Software-Defined Vehicles >IFX.FF

2025. g. 7. apr. 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Infineon: Business Expected to Generate Rev of $225M-$250M in Calendar Yr 2025 With Gross Margin of Around 60% >IFX.FF

2025. g. 7. apr. 21:32 UTC

Iegādes, apvienošanās, pārņemšana

Infineon: Enters Agreement for Acquisition of Marvell Technology's Automotive Ethernet Business for US$2.5 B >IFX.FF

2025. g. 7. apr. 21:31 UTC

Top Ziņas

Apple Plans to Source More iPhones From India as Potential Tariff Fix -- Update

2025. g. 7. apr. 21:29 UTC

Top Ziņas

PNC Names Former BlackRock Star Mark Wiedman as President -- WSJ

2025. g. 7. apr. 21:28 UTC

Iegādes, apvienošanās, pārņemšana

Infineon Further Strengthens Its Number One Position In Automotive Microcontrollers And Boosts Systems Capabilities For Software-defined Vehicles With Acquisition Of Marvell's Automotive Ethernet Business >IFNNY MRVL

2025. g. 7. apr. 21:21 UTC

Top Ziņas

Defense Stocks Can't Escape the Trade War. Expect to Hear This Term. -- Barrons.com

2025. g. 7. apr. 21:18 UTC

Top Ziņas
Peļņas

Levi Strauss Trying to Mitigate Tariff Impact on Consumer; Company Grows Revenue -- Update

2025. g. 7. apr. 21:17 UTC

Peļņas

Levi Sees U.S. Consumer 'Generally Resilient,' CFO Says

2025. g. 7. apr. 21:17 UTC

Peļņas

Levi Looking at Cost-Related Opportunities, Pricing Changes as Part of Response, CFO Says

2025. g. 7. apr. 21:16 UTC

Peļņas

Levi Strauss Sets Up Task Force to Understand Implications of Trump's Tariffs, CFO Singh Says

2025. g. 7. apr. 21:16 UTC

Top Ziņas

What to Know About Trump's Latest Tariffs -- 3rd Update

2025. g. 7. apr. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Marvell to Sell In-Vehicle Network Portfolio for $2.5B

2025. g. 7. apr. 21:14 UTC

Top Ziņas

PNC Taps Ex-BlackRock Star Mark Wiedman as President -- WSJ

2025. g. 7. apr. 21:06 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Trump Orders New Review of Nippon-U.S. Steel Merger -- 3rd Update

2025. g. 7. apr. 21:03 UTC

Top Ziņas

Even Google Could Feel the Sting of a Trade War -- Barrons.com

2025. g. 7. apr. 20:59 UTC

Top Ziņas

U.S. Stock Meltdown Gives Way to Global Rout -- WSJ

2025. g. 7. apr. 20:56 UTC

Galvenie tirgus virzītāji

Broadcom Authorizes $10B Share Repurchase Program

2025. g. 7. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

97.77% augšup

Prognoze 12 mēnešiem

Vidējais 15.96 USD  97.77%

Augstākais 22 USD

Zemākais 11 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

13 ratings

6

Pirkt

4

Turēt

3

Pārdot

Tehniskais rādītājs

By Trading Central

7.88 / 9.19Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

70 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.